Maternal Thyroid Function in Early Pregnancy and Child Attention-Deficit Hyperactivity Disorder: An Individual-Participant Meta-Analysis

Deborah Levie, MSc¹⁻⁶, Tim IM Korevaar, MD¹⁻², Tessa A Mulder, BSc¹⁻³, Sarah C Bath, PhD⁷, Mariana Dineva, BSc⁷, Maria-Jose Lopez-Espinosa, PhD^{6,9} Mikel Basterrechea, MSc^{6,8,13}, Loreto Santa Marina, MSc^{6,8,13} Marisa Rebagliato, MD^{6,9,10}, Jordi Sunyer, MD^{4-6,11}, Margaret P Rayman, DPhil⁷, Henning Tiemeier, MD^{3,12}, Robin P Peeters*, MD², Mònica Guxens*, MD³⁻⁶

*These authors contributed equally

- 1 The Generation R Study Group, Erasmus University Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands
- 2 Department of Internal Medicine, Academic Center For Thyroid Diseases, Erasmus University Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands
- 3 Department of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Centre—Sophia Children's Hospital, PO Box 2060, 3000 CB, Rotterdam, The Netherlands
- 4 ISGlobal, Carrer Doctor Aiguader 88, 08003 Barcelona, Spain
- 5 Pompeu Fabra University, Barcelona, Carrer Doctor Aiguader 88, 08003 Barcelona, Spain
- 6 Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida Monforte de Lemos 3-5, 28029 Madrid, Spain
- 7 Department of Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, United Kingdom
- 8 Departamento de Sanidad Gobierno Vasco, Subdirección de Salud Pública de Guipúzcoa, Avda. Navarra, 4. 20013 Donostia – San Sebastián, Spain
- 9 Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I- Universitat de València, Avenida de Catalunya 21, 46020 Valencia, Spain

- 10 Departamento de Medicina, Universitat Jaume I, Avd. Vicente Sos Baynat s/n, E-12071 Castelló de la Plana, Spain
- 11 Hospital del Mar Research Institute (IMIM), Carrer Doctor Aiguader 88, 08003 Barcelona, Spain
- 12 Department of Social and Behavioral Science, Harvard TH Chan School of Public Health, 677 Huntington Avenue, Boston MA 02115, USA
- 13 Biodonostia Health Research Institute, Paseo Doctor Beguiristain s/n 20014, San Sebastian, Basque Country, Spain.

Email addresses authors

Deborah Levie: d.levie@erasmusmc.nl; Tim IM Korevaar: t.korevaar@erasmusmc.nl; Tessa A Mulder: t.a.mulder@erasmusmc.nl; Sarah C Bath: s.bath@surrey.ac.uk; Mariana Dineva: m.dineva@surrey.ac.uk; Mikel Basterrechea: m-basterretxea@euskadi.eus; Maria-Jose Lopez-Espinosa: lopez_josp@gva.es; Marisa Rebagliato: rebaglia@med.uji.es; Loreto Santa Marina: ambien4ss-san@euskadi.eus; Jordi Sunyer: jordi.sunyer@isglobal.org; Margaret P Rayman: m.rayman@surrey.ac.uk; Henning Tiemeier: tiemeier@hsph.harvard.edu; Robin P Peeters: r.peeters@erasmusmc.nl; Mònica Guxens: monica.guxens@isglobal.org

Running title: Maternal thyroid function and child ADHD

Keywords: thyroxine; behavioral problems; neurodevelopmental disorders; INMA; Generation R; ALSPAC.

Abstract

Background: Thyroid hormone is essential for optimal fetal brain development. Evidence suggests that both low and high maternal thyroid hormone availability may have adverse effects on child neurodevelopmental outcomes, but the effect on behavioral problems remains unclear. We studied the association of maternal thyrotropin (TSH) and free thyroxine (FT4) concentrations during the first 18 weeks of pregnancy with child Attention-Deficit Hyperactivity Disorder (ADHD).

Methods: 7669 mother-child pairs with data on maternal thyroid function and child ADHD were selected from three prospective population-based birth cohorts: INMA (N=1073, Spain), Generation R (N=3812, The Netherlands) and ALSPAC (N=2784, United Kingdom). Exclusion criteria were multiple pregnancies, fertility treatments, usage of medication affecting the thyroid, and pre-existing thyroid disease. We used logistic regression models to study the association of maternal thyroid function with the primary outcome, ADHD, assessed via the DSM-IV criteria by parents and/or teachers at a median child age of 4.5 to 7.6 years, and with the secondary outcome, an ADHD symptom score above the 90th percentile. Effect modification by gestational age and sex was tested with interaction terms and stratified analyses.

Results: Overall, 233 (3%) children met the criteria for ADHD. When analyzed continuously, neither FT4 nor TSH was associated with a higher risk of ADHD [Odds ratio (OR), 95% Confidence Interval (CI): 1.1 (1.0-1.3), $P=0.060$ and OR 0.9, 95% CI 0.9-1.1, $P=0.385$, respectively] or with high symptom scores. When investigating effect modification by gestational age, a higher FT4 was associated with symptoms above the 90th percentile but only in the first trimester [for FT4 per 1SD: OR 1.2 (95% CI 1.0-1.4),

$P=0.027$]. However, these differential effects by gestational age were not consistent. No significant effect modification by sex was observed.

Conclusions: We found no clear evidence of an association between maternal thyroid function and child ADHD.

Introduction

Thyroid hormone regulates important brain developmental processes including early

neuronal proliferation and migration (1). Until mid-gestation, fetal thyroid hormone availability largely depends on the supply of maternal thyroid hormone *via* the placenta (2). Relatively mild deficits in thyroid hormone availability have been associated with adverse child neurodevelopmental outcomes, such as lower IQ, lower psychomotor development scores, and lower grey matter and cortex volume (3–5). Evidence from mainly animal studies also suggests that high-normal thyroid hormone availability may have similar adverse effects on neurodevelopmental outcomes (5–11). However, whether mild changes in thyroid hormone concentrations also play a role in the etiology of child behavioral problems is less well established.

Attention-Deficit Hyperactivity Disorder (ADHD) is a “persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequently displayed than is typically observed in individuals at a comparable level of development” (12) and occurs in approximately 5.9 to 7.1 percent of children and adolescents (13). The exact cause of ADHD is unknown, but susceptibility is thought to depend on genetic predisposition, environmental factors and their interactions (14, 15). There is some indication that high thyroid hormone availability may increase the risk of ADHD. Patients with resistance to thyroid hormone beta (RTH β), in which a defective thyroid hormone receptor beta (TR β) results in lifelong exposure to a high thyroid hormone concentration in tissues that predominantly express thyroid hormone receptor alpha (TR α) such as the brain, have a higher risk of ADHD (16). Furthermore, individuals with ADHD have a delay in cortical maturation, reduced neuronal activity and brain volume (17–19) compared to healthy controls; some of the same abnormalities are also seen in the offspring of mothers with gestational thyroid dysfunction (5, 20–22). However, further studies are required to

clarify whether too low and/or too high thyroid hormone availability in pregnancy is consistently associated with the development of ADHD.

So far, evidence from epidemiological studies is inconsistent with regard to an association of maternal thyroid function with child ADHD (23–31). Some studies indicated that the effects of maternal thyroid function on ADHD may be more prominent in girls (23, 31), but further studies are needed to replicate and further clarify sex-specific effects. In addition, it would be relevant to investigate whether there are differential effects by gestational age, as the relatively late start of levothyroxine therapy in women with subclinical hypothyroidism or hypothyroxinemia in two randomized control trials has been suggested to be a reason for the negative findings for those trials (32, 33). We therefore combined data from three prospective birth cohorts to study the association between FT4 and TSH in early pregnancy and the risk of ADHD, as well as the effect modification by child sex and gestational age.

Material and Methods

Study design and populations

We used data from three population-based birth cohort studies: INfancia y Medio Ambiente (INMA; Spain, sub-cohorts of Valencia, Sabadell, and Gipuzkoa), Generation R (The Netherlands), and the Avon Longitudinal Study of Parents and Children (ALSPAC, United Kingdom). Information on the designs of the three cohort studies can be found elsewhere (34–37); the ALSPAC study website contains details of all the data that is available through a searchable data dictionary and variable search tool (38). Briefly, all three cohorts were designed to understand the role of environmental

exposures and/or genetic characteristics for child growth, development and health from fetal life until (young) adulthood. The INMA Project is a network of seven birth cohorts in Spain with different recruitment periods. Pregnant women included in the Valencia (N=855), Sabadell (N=657), and Gipuzkoa (N=638) cohorts enrolled from November 2003 until June 2005, July 2004 until July 2006, and April 2006 until January 2008, respectively. In Generation R, 9778 mothers with a delivery date from April 2002 until January 2006 were enrolled in the study. In ALSPAC, pregnant women resident in Avon, UK with expected dates of delivery between April 1991 and December 1992 were invited to take part in the study. The initial number of pregnancies enrolled was 14541 of which 13998 children were alive at the first year of age. For the current study, mother-child pairs were eligible if they had a thyroid measurement in the first half of pregnancy (≤ 18 weeks) and had data on an assessment of ADHD symptoms during childhood. Exclusion criteria were multiple pregnancies, fertility treatment, usage of medication affecting thyroid function during pregnancy and pre-existing thyroid disease. Ethical approval was obtained prior to recruitment and during the follow-up waves of data collection from a number of bodies: the Ethical Committee of the Municipal Institute of Medical Investigation, the Ethical Committees of the hospitals involved in the study (INMA; reference numbers G03/176, 2005/2106/I, and 2009/3432/I), the Medical Ethical Committee of the Erasmus Medical Center (Generation R; reference numbers: MEC 198.782.2001.31, MEC-2007-413), the ALSPAC Ethics and Law Committee, and the Local Research Ethics Committees [ALSPAC; reference numbers available at (39)]; approval by participants and/or parents or guardians of the children was given by a signed informed-consent form.

Maternal thyroid function

The procedures and methodologies by which maternal thyroid function was measured differed among cohorts. In INMA, serum samples were collected at a mean [$\pm$ standard deviation (SD)] gestational age of 13.1 ± 1.3 weeks and stored at -80°C after collection. FT4 and TSH were measured using a solid-phase, time-resolved sandwich fluoro-immunoassay (AutoDEL-FIA, PerkinElmer Life and Analytical Sciences, Wallac Oy, Turku, Finland) and a lanthanide metal europium (Eu) label. Thyroid peroxidase antibodies (TPOAbs) were not measured. In Generation R, serum samples were collected at a mean $\pm$ SD age of 13.4 ± 1.9 weeks, centrifuged and stored at -80°C after collection. FT4 and TSH were measured using the Vitros ECI immunodiagnostic (Ortho clinical Diagnostics, Rochester, NY, USA). Maternal TPOAbs were measured using the Phadia 250 immunoassay (Phadia AB, Uppsala, Sweden) and a TPO titre ≥ 60 IU/mL was considered as positive. In ALSPAC, serum samples were collected at a mean $\pm$ SD age of 11.0 ± 3.2 weeks and stored at -20°C . FT4, TSH, and TPOAb measurements were performed using Abbott Architect i2000. A TPO titre ≥ 6 IU/mL was considered as positive. Additional information about the serum measurements is provided in the Supplementary Material.

ADHD symptoms

In INMA, ADHD symptoms were assessed by teachers at a median age of 4.5 years [interquartile range (IQR) 4.4-5.7 years] using the ADHD Criteria of Diagnostic and Statistical Manual of Mental Disorders, fourth edition (ADHD-DSM-IV) list (12). The

DSM criteria are a valid tool for diagnosing ADHD, already at a pre-school age (40). The DSM-IV consists of questions on nine inattention symptoms and nine hyperactivity-impulsivity symptoms on a four-point Likert scale (never or rarely, sometimes, often, or very often), designed to score ADHD symptoms present in the last six months prior to the assessment. A symptom was defined as present if the question was answered with “often” or “very often”. The total symptom score consisted of the sum of all the inattention and hyperactivity-impulsivity symptoms. Based on the symptom criteria of the DSM-IV, an ADHD diagnosis was given when the child had at least six inattention and/or six hyperactivity-impulsivity symptoms.

In Generation R, parents assessed their child’s behavior in the last two months at a median age of 6.0 years (IQR 5.9-6.2 years) using the Child Behavior Checklist 1½–5 (CBCL/1½–5) (41). From this 99-item questionnaire, the sum score of six questions on a three-point Likert scale (not true, somewhat or sometimes true, very true or often true) made up the total ADHD symptom score. In addition, the computer-assisted Diagnostic Interview Schedule for Children - Young Child version (42), which is a DSM-IV based interview, was administered by research assistants at a median age of 6.6 years (IQR 6.3-7.1 years) to the parents or caregivers of a selected group of children. This subgroup consisted of a random selection of negative controls and children with a high probability of a psychiatric disorder, e.g., children who scored in the top 15th percentile of the CBCL1½–5 total problem score and/or in the top two percent of the syndrome scale scores. Algorithms provided by the developers of this tool were used to derive a DSM-IV diagnosis based on the symptom criteria of the DSM-IV. More information on the procedures and assessment is described elsewhere (43). In our study, the reference

group consisted of children that were not identified as having ADHD and children who did not have data on the Diagnostic Interview Schedule-Young Child version, but did have data on ADHD symptoms as assessed with the CBCL/1½–5 (e.g. mostly children with a low probability of a psychiatric disorder).

In ALSPAC, the Development and Well-Being Assessment (DAWBA) was used to evaluate child psychological disorders at a median age of 7.6 years (IQR 7.6-7.7 years) (44). This validated tool consists of questions based on the diagnostic criteria described in the International Classification of Diseases, Tenth Edition (ICD-10) or the DSM-IV. A semi-structured interview was administered to parents relating to inattention and hyperactivity symptoms present in the six months prior to the assessment. Teachers in the geographically defined study area were also requested to fill the DAWBA questionnaire on all children with a birth date between April 1991 and December 1992. The teacher completion was 37% for ALSPAC children (45). Clinical raters reviewed all available ratings on ADHD symptoms and assigned an ADHD diagnosis using the DSM-IV criteria as if in clinical settings.

Covariates

During pregnancy questionnaires were used to collect information on maternal age, parity (zero, one, and two or more), pre-pregnancy body mass index (BMI), smoking during pregnancy (never, smoked in the beginning or until pregnancy confirmed, continued smoking), ethnicity/country of birth (cohort-specific categories), and maternal educational level (low, middle, high). Gestational age at blood sampling was defined using ultrasound and/or last menstrual period. Information on sex of the child was

obtained from community midwives, obstetricians, hospital registries, clinical records or questionnaires. Age at ADHD assessment was obtained during the study visit.

Statistical analyses

Owing to the differences in assays, the absolute values of TSH and FT4 across the cohorts cannot be compared. We therefore calculated cohort-specific SD scores with a mean of 0 and a SD of 1 using logarithmically transformed values of FT4 and TSH based on TPOAb-negative women when possible. Values outside the mean $\pm$ 4 SD range were considered as outliers and excluded from further analyses. We assessed the association of maternal TSH and FT4 SD scores within the mean $\pm$ 4 SD range with child ADHD by performing multivariable logistic regression models using pooled data. We used the same model to study the association with our secondary outcome, an ADHD symptom score above the 90th percentile which was generated in each cohort separately. This extra harmonized cut-off was chosen *a priori* to increase statistical power owing to the low prevalence of children meeting the criteria of ADHD and has been used previously to define children at risk (46, 47). Negative binomial regression models were used to assess the association of FT4 and TSH with total ADHD symptom scores on a continuous scale per cohort. We could not analyze these associations using pooled data, since the symptom scores did not share a common metric between cohorts and therefore were not comparable. We tested for non-linearity by adding a quadratic term to our models and we assessed multicollinearity between covariates by the variance inflation factor. All cohort-specific models were adjusted for all the mentioned covariates. However, in the pooled analyses we could not adjust for child age at ADHD ascertainment, maternal ethnicity/country of birth, and cohort simultaneously. The

categories or the range of these variables did not overlap i.e. they were cohort-specific, and adjusting for several of these variables at the same time causes multicollinearity. Therefore in the pooled analyses we chose to adjust for maternal ethnicity/country of birth, because it is known that there are ethnic differences in maternal thyroid parameters during pregnancy (48–50), and ethnicity is intertwined with social economic status, which has been associated with behavioral problems (51) and ADHD (13, 52). We investigated whether adjusting for cohort instead of ethnicity/country of birth yielded different results. The results were similar. We therefore chose to show the results based on the ethnicity/country of birth adjustment. We decided to present standard logistic regression models after comparison with multilevel models using the Akaike information criterion.

We performed several sensitivity analyses. First, we tested for heterogeneity between cohorts using the Cochran Q test and the I^2 statistic [Supplementary Figure 1; (53)]. Second, we also compared the effect estimates before and after excluding TPOAb positive women in mother-child pairs of which TPOAb status was known, e.g. Generation R and ALSPAC, since TPOAb positivity was associated with a higher risk of ADHD irrespective of maternal TSH (54). Third, we tested for possible effect modification by sex and/or gestational age at blood sampling by adding product terms into the models. To identify potential relevant effect modifiers, we screened for interaction terms with a *P*-value of <0.15 and subsequently performed stratified analyses to verify and quantify any relevant differences. For gestational age, analyses were stratified by tertiles based on pooled data (< 11.8 weeks, ≥ 11.8 to ≤ 13.5 weeks, and > 13.5 weeks).

The percentage of missing covariate data ranged from 0% to 15.6% (Table 1). Before pooling the cohort data, missing values in these covariates were imputed using chained equations, generating 25 datasets. Additionally, to alleviate the potential bias that arises when only the population with available data on maternal thyroid function and child ADHD symptoms is included, we applied inverse probability weighting (55). Briefly, we used data on characteristics available for all participants at recruitment to predict the probability of participation in the study, and an inverse of those probabilities as weights in the analyses so that results would be representative for the initial populations of the cohorts. Statistical analyses were performed in STATA (version 15.0; Stata Corporation, College Station, TX).

Results

After exclusions, data for a total of 7669 mother-child pairs were available for analyses (Figure 1). An overview of the characteristics of the study population is given in Table 1. The prevalence of ADHD was 5.3% (n=57) in INMA, 3.2% (n=121) in Generation R, and 2.0% (n=55) in ALSPAC. Compared to the study population, women who were not included in the analysis had a lower education level, were less often native or Caucasian, and were younger in all three cohorts (Supplementary Table 1). There were similar differences in characteristics when comparing mothers whose children had an ADHD symptom score and those whose children did not undergo an ADHD assessment (Supplementary Table 2). No clinically relevant differences were found in TSH and FT4 concentrations between these two groups.

ADHD

FT4 was not associated with ADHD [OR 1.1, 95% Confidence Interval (CI) 1.0 to 1.3, $P=0.060$; Table 2 and Supplementary Figure 1]. The effect estimate remained similar after excluding TPOAb positive women. There was no effect modification by gestational age (P for interaction term= 0.581). While there was no indication of significant effect modification by child's sex (P for interaction term= 0.144), we did observe a significant association in girls only (OR 1.3, 95% CI 1.0 to 1.7, $P=0.042$; for boys: OR 1.1, 95% CI 0.9 to 1.3, $P=0.352$). The association in girls became stronger after excluding TPOAb positive women from mother-child pairs of which TPOAb status was known (from OR 1.2, 95 % CI 0.9 to 1.7, $P=0.187$ to OR 1.5, 95% CI 1.1 to 2.1, $P=0.020$), while the effect estimate remained similar in boys.

TSH was not associated with ADHD (OR 0.9, 95%CI 0.8 to 1.1, $P=0.385$; Table 2 and Supplementary Figure 1) and the effect estimate remained similar after excluding TPOAb positive women. There was no effect modification by gestational age (P for interaction term= 0.757 ; Table 3) or child sex (P for interaction term= 0.474).

ADHD symptom score above the 90th percentile

There was no association of FT4 with an ADHD symptom score above the 90th percentile (OR 1.0, 95%CI 0.9 to 1.1, $P=0.554$, respectively; Table 2 and Supplementary Figure 1) and no indication of effect modification by child's sex. We did identify a possible effect modification by gestational age for the association of FT4 with symptoms above the 90th percentile (P for interaction term: 0.013); a higher FT4 was associated with a significant 1.2-fold higher risk of ADHD symptoms above the 90th

percentile in the early-pregnancy FT4 measurements (95% CI 1.0 to 1.4, $P=0.027$; < 11.8 weeks), while a higher FT4 was associated with a lower risk in mother-child pairs with relatively late-pregnancy FT4 measurements (OR 0.9, 95% CI 0.7 to 1.0, $P=0.045$; Table 3). The effect estimates remained similar after excluding TPOAb positive women.

There was no association of TSH with an ADHD symptom score above the 90th percentile (OR 0.9, 95%CI 0.9 to 1.0, $P=0.073$, respectively; Table 2 and Supplementary Figure 1) and no indication of effect modification by child's sex. We identified a possible effect modification by gestational age for the association of TSH with symptom scores above the 90th percentile (P for interaction term: 0.082). Stratified analyses by tertile of gestational age showed that a higher TSH was associated with a significant 0.8-fold lower risk of ADHD symptoms above the 90th percentile in the relatively early-pregnancy TSH measurements (95% CI 0.7 to 0.9, $P=0.006$; Table 3, < 11.8 weeks). The effect estimates remained similar after excluding TPOAb positive women.

ADHD symptoms on a continuous scale

No associations were identified between FT4 or TSH across the full range and the total ADHD symptom score as investigated in each cohort separately (Supplementary Table 3 and 4).

Discussion

We did not identify an association between FT4 and TSH and ADHD in the overall study population. There was inconsistent evidence that the associations investigated were different depending on gestational age.

While both low and high-normal maternal FT4 concentrations have been associated with adverse outcomes related to fetal brain development (3–11), the role of thyroid hormone in the development of ADHD is unknown. Exposure to high thyroid hormone concentrations might contribute to the etiology of this disorder, since individuals with generalized resistance to thyroid hormone were shown to be more prone to meet the criteria for ADHD than subjects without this mutation (16). Fetuses without the mutation but born to a mother with RTH β , had reduced sensitivity to thyroid hormone than fetuses born to mothers without RTH β (56). The reduced sensitivity to thyroid hormone was explained by increased deiodinase 3 (D3) expression in the anterior pituitary. Other studies have also shown that untreated hyperthyroidism during pregnancy may lead to persistent changes in the thyroid function of the child (57, 58). In addition, children born to mothers with RTH β were found to have lower birth weight (59). Lower birth weight and small size for gestational age, which has been already shown to be associated with a higher FT4 concentration in pregnancy in Generation R and INMA (60, 61), could be on the causal pathway to ADHD symptomatology (62).

Thus far, the results of studies on the association between maternal thyroid function and child ADHD are inconsistent. While one study reported a positive association between FT4 and ADHD symptoms (26), other studies either report no association (23, 24, 28, 30) or a negative association (27, 29, 31). Likewise for TSH, studies show either a positive association between TSH and attention problems or

ADHD symptoms (23–25), no association (26–29, 31) or a possible protective effect of a higher TSH concentration (30). There may be different explanations as to why some studies found an association between FT4 or TSH and ADHD, while others did not. First of all, although FT4 and TSH both reflect thyroid status, TSH is a more sensitive reflection of thyroid autoimmunity, which is associated with ADHD (54). Second, the inconsistent study results may also be explained by several methodological points. ADHD symptoms were assessed differently between studies, with some earlier studies using tools that did not include an extensive set of items as the DSM-IV uses to classify ADHD. In addition, ADHD was defined differently across studies – by medical diagnosis (26, 31), symptoms on a continuous scale (24, 27, 30) or by ADHD or inattention symptom cut-offs (23, 25, 28, 29) – hence the comparability between studies is limited. The latter studies did not use a symptom score above the 90th percentile, as used in our study. Third, iodine status may also explain part of the heterogeneity between studies (63). Results in a small study population showed that ADHD prevalence was higher in an iodine-deficient area than in an iodine-sufficient area (64).

The importance of maternal thyroid hormone for the fetal brain changes throughout pregnancy. Before the fetal thyroid is functionally mature at 18-20 weeks gestation, the fetus depends on thyroid hormone from the mother (1). During the second half of pregnancy the maternal thyroid remains an important source, but to a lesser extent as considerable amounts of thyroid hormone are produced by the fetus itself (2). We investigated whether the effect of maternal thyroid hormone on ADHD (symptoms) differed by gestational age. The proportion of mother-child pairs were not equally distributed across the different groups of gestational age; in roughly the first 12 weeks of

gestation, two thirds of the mother-child pairs were from the ALSPAC cohort. Stratified analyses showed that the association of higher FT4 with a higher risk of symptom score above the 90th percentile was prominent in roughly the first 12 weeks of gestation, but not thereafter. Given these findings and the physiologically interrelation between FT4 and TSH, we could also observe that a higher TSH was associated with a lower risk of symptom scores above the 90th percentile only in the first trimester. However, there was no significant interaction with gestational age in the association of FT4 or TSH with ADHD. From our analyses, we therefore have no strong evidence for differential effects by gestational age.

Interestingly, in the current study a higher maternal FT4 concentration during pregnancy was associated with a higher risk of ADHD in girls only. Differential effects of thyroid hormone on brain development related outcomes by sex have been reported previously (23, 31) and it is well known that ADHD is more often diagnosed in males. While it remains unclear why this association may be sex-specific, it is known that child sex modifies the thyroïdal response to human chorionic gonadotropin (hCG); women pregnant with a female fetus have a higher thyroïdal response to high hCG concentrations, resulting in lower TSH and higher FT4, than those with a male fetus (65). However, our results have to be interpreted with caution as no significant interaction with sex was found. Further studies are needed to replicate if there are sex-specific effects of thyroid hormone on brain development.

Observational studies showed that both low and high maternal thyroid function are associated with lower child IQ and lower grey matter volume (3, 5, 25). Randomized trials thus far failed to show a benefit of levothyroxine treatment in pregnant women with

subclinical hypothyroidism or hypothyroxinemia on child IQ (32, 33), but these trials have been limited by a suboptimal timing and dose of treatment (66). Behavior problems such as ADHD could also be considered an outcome that may reflect suboptimal fetal brain development during pregnancy. Our study shows no association between maternal thyroid function and child ADHD. However, owing to the observational design of this study, we cannot make statements on what the potential effects of this treatment on behavior problems in children would be.

We were able to combine data from three large cohorts, enabling us to investigate associations between thyroid function and ADHD in a large number of mother-child pairs. All three cohorts used the DSM, internationally applied, diagnostic criteria, which are the most used clinically for diagnosing psychiatric disorders. Using individual-participant data instead of aggregate data facilitated the use of consistent inclusion and exclusion criteria and standardized statistical analyses across cohort studies. Combining individual participant data into a meta-analysis offers further advantages over individual studies. Irrespective of a replication of findings as found in individual studies, findings from meta-analyses enriches our knowledge on the theory tested and increases confidence in generalization.

In our study ADHD occurred in only 3 percent of children, which may have been a low proportion in which to detect an association. This prevalence was lower than that reported in children and adolescents in a systematic review (13). The prevalence of ADHD in Generation R was lower than previously reported due to a different sample size and we did not report a weighted prevalence to represent the full sample with CBCL1½–5 data (43). Prevalence estimates are known to vary widely by individual

studies. Part of this variability may be explained by the diagnostic criteria used to define ADHD, the method used to assess ADHD symptoms, the incorporation of functional impairments as part of the definition of ADHD, and possibly also by social economic status of the population (13). In our study mother-child pairs with a lower social economic status (e.g. lower maternal educational level and less often native or Caucasian) were more likely to be lost to follow-up. We accounted for potential differential loss to follow-up by applying inverse probability weighting. To increase statistical power, we used the highest 10% of ADHD symptoms as a secondary outcome. It should be noted that this extra cut-off was arbitrarily chosen and has not been validated.

A limitation of this study is that ADHD symptoms were assessed at different ages using different methods, including inconsistency in the type of assessor used by the different cohorts, which may have contributed to heterogeneity in results. The heterogeneity by the latter was shown by a recent study showing that maternal thyroid function was associated with teacher-rated ADHD symptoms, but not with parental ratings (29). Due to low-to-moderate agreement between teacher and parental observations, multi-informant assessment has been recommended in order to understand the behavior of a child in different settings (67, 68); this was most closely adhered to in ALSPAC. We did not have the opportunity to re-score the data that was collected of a sample of children using the three methods. In addition, we had no data on clinical diagnosis of ADHD by a medical doctor, which may have caused outcome misclassification.

In conclusion, the results of the current study do not show an association between maternal thyroid function and ADHD in the overall study population. As the etiology of ADHD as well as the potential role of thyroid hormone availability remains poorly understood, further studies are warranted.

Acknowledgements

EUthyroid Project: European Union's Horizon 2020 research and innovation programme under grant agreement No 634453.

INMA, Spain: This study was funded by grants from EU (FP7-ENV-2011 cod 282957, HEALTH.2010.2.4.5-1, and 733206) and Spain: Instituto de Salud Carlos III (Red INMA G03/176; CB06/02/0041; FIS-FEDER: PI041436, PI05/1079, PI06/0867, PI081151, FIS-and PS09/00090, PI11/01007, PI11/02591, PI11/02038, PI13/1944, PI13/2032, PI14/00891, PI14/01687, PI16/1288, and PI17/00663; Miguel Servet-FEDER CP11/00178, CP15/00025, and CPII16/00051, and Miguel Servet-FSE MS13/00054, and MSII16/00051), Generalitat Valenciana: FISABIO (UGP 15-230, UGP-15-244, and UGP-15-249), Alicia Koplowitz Foundation 2017, Generalitat de Catalunya-CIRIT 1999SGR 00241, Fundació La marató de TV3 (090430), Department of Health of the Basque Government (2005111093 and 2009111069), and the Provincial Government of Gipuzkoa (DFG06/004 and DFG08/001).

Generation R, The Netherlands: The Generation R Study is conducted by the Erasmus Medical Center in close collaboration with the Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, Rotterdam, and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (STAR-

MDC), Rotterdam. The Generation R Study is supported by the Erasmus Medical Center, Rotterdam, the Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Netherlands Organization for Scientific Research (NWO), the Ministry of Health, Welfare and Sport. A grant from the Sophia Children's Hospital Research Funds supports the neurodevelopmental work on thyroid; Robin P. Peeters is supported by a clinical fellowship from ZonMw, project number 90700412. Henning Tiemeier is supported by a VICI grant with personal grant number 016.VICI.170.200.

ALSPAC, United Kingdom: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol currently provide core support for ALSPAC. The publication is the work of the authors and Mònica Guxens will serve as guarantor for the contents of this paper. Data collection is funded from a wide range of sources, which are detailed on the ALSPAC website: <http://www.bristol.ac.uk/alspac/about/>.

We would like to thank the participants of all cohorts for their generous collaboration; Professor Scott Nelson, University of Glasgow, UK, for the ALSPAC thyroid measurements which were funded by the Chief Scientist Office, Scotland (ETM 97/0357/130024782); Ane M. Castilla of the Public Health Laboratory of Bilbao, Spain, for the thyroid measurements in INMA, and Professor dr. Yolanda de Rijke, of the

department of Clinical Chemistry, Erasmus MC, University Medical Center, the Netherlands for design and measurements of the thyroid measurements in Generation R.

Disclosure statement. No competing financial interests exist.

Correspondence to:

Mònica Guxens

Barcelona Institute for Global Health (ISGlobal), Campus Mar

Doctor Aiguader, 88, 08003 Barcelona, Spain.

Tel. +34 932 147 394 | Fax +34 932 147 301.

Email: monica.guxens@isglobal.org

References

1. Williams GR 2008 Neurodevelopmental and Neurophysiological Actions of Thyroid Hormone. *Journal of Neuroendocrinology* **20**:784–794.
2. Thorpe-Beeston JG, Nicolaides KH, Felton CV, Butler J, McGregor AM 1991 Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. *N Engl J Med* **324**:532–536.
3. Levie D, Korevaar TIM, Bath SC, Dalmau-Bueno A, Murcia M, Espada M, Dineva M, Ibarluzea JM, Sunyer J, Tiemeier H, Rebagliato M, Rayman MP, Peeters RP, Guxens M 2018 Thyroid Function in Early Pregnancy, Child IQ, and Autistic Traits: a Meta-analysis of Individual-participant Data. *J Clin Endocrinol Metab* **103**:2967–2979.
4. Pop VJ, Kuijpers JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, Vulsma T, Wiersinga WM, Drexhage HA, Vader HL 1999 Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clinical endocrinology* **50**:149–155.
5. Korevaar TIM, Muetzel R, Medici M, Chaker L, Jaddoe VWV, de Rijke YB, Steegers EAP, Visser TJ, White T, Tiemeier H, Peeters RP 2016 Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. *Lancet Diabetes Endocrinol* **4**:35–43.
6. Marta CB, Adamo AM, Soto EF, Pasquini JM 1998 Sustained neonatal hyperthyroidism in the rat affects myelination in the central nervous system. *J Neurosci Res* **53**:251–259.

7. Nicholson JL, Altman J 1972 The effects of early hypo- and hyperthyroidism on the development of rat cerebellar cortex. I. Cell proliferation and differentiation. *Brain Res* **44**:13–23.
8. Nicholson JL, Altman J 1972 The effects of early hypo- and hyperthyroidism on the development of the rat cerebellar cortex. II. Synaptogenesis in the molecular layer. *Brain Research* **44**:25–36.
9. Ahmed OM, El-Gareib AW, El-bakry AM, Abd El-Tawab SM, Ahmed RG 2008 Thyroid hormones states and brain development interactions. *International Journal of Developmental Neuroscience* **26**:147–209.
10. Lauder JM 1977 The effects of early hypo- and hyperthyroidism on the development of rat cerebellar cortex. III. Kinetics of cell proliferation in the external granular layer. *Brain Res* **126**:31–51.
11. Lauder JM, Altman J, Krebs H 1974 Some mechanisms of cerebellar foliation: effects of early hypo- and hyperthyroidism. *Brain Res* **76**:33–40.
12. American Psychiatric Association 2000 Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, Washington, DC.
13. Willcutt EG 2012 The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review. *Neurotherapeutics* **9**:490–499.
14. Banerjee TD, Middleton F, Faraone SV Environmental risk factors for attention-deficit hyperactivity disorder. *Acta Paediatrica* **96**:1269–1274.
15. Nigg J, Nikolas M, Burt SA 2010 Measured Gene by Environment Interaction in Relation to Attention-Deficit/Hyperactivity Disorder (ADHD). *J Am Acad Child Adolesc Psychiatry* **49**:863–873.

16. Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, Mixson AJ, Weintraub BD 1993 Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. *N Engl J Med* **328**:997–1001.
17. Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch J P, Greenstein D, Clasen L, Evans A, Giedd J, Rapoport JL 2007 Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. *PNAS* **104**:19649–19654.
18. Zang Yu-Feng, He Yong, Zhu Chao-Zhe, Cao Qing-Jiu, Sui Man-Qiu, Liang Meng, Tian Li-Xia, Jiang Tian-Zi, Wang Yu-Feng 2007 Altered baseline brain activity in children with ADHD revealed by resting-state functional MRI. *Brain and Development* **29**:83–91.
19. Castellanos FX, Lee, Patti P., Sharp, Wendy, Jeffries, Neal O., Greenstein, Deanna K., Clasen, Liv S., Blumenthal, Jonathan D., James, Regina S., Ebens, Christen L., Walter, James M., Zijdenbos, Alex, Evans, Alan C., Giedd, Jay N., Rapoport, Judith L. 2002 Developmental Trajectories of Brain Volume Abnormalities in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. *JAMA* **288**:1740–1748.
20. Lischinsky JE, Skocic J, Clairman H, Rovet J 2016 Preliminary Findings Show Maternal Hypothyroidism May Contribute to Abnormal Cortical Morphology in Offspring. *Front Endocrinol (Lausanne)* **7**:16.
21. Samadi A, Skocic J, Rovet JF 2015 Children Born to Women Treated for Hypothyroidism During Pregnancy Show Abnormal Corpus Callosum Development. *Thyroid* **25**:494–502.
22. Willoughby KA, McAndrews MP, Rovet JF 2013 Effects of Maternal Hypothyroidism on Offspring Hippocampus and Memory. *Thyroid* **24**:576–584.

23. Pääkilä F, Männistö T, Pouta A, Hartikainen A-L, Ruokonen A, Surcel H-M, Bloigu A, Vääräsmäki M, Järvelin M-R, Moilanen I, Suvanto E 2014 The Impact of Gestational Thyroid Hormone Concentrations on ADHD Symptoms of the Child. *J Clin Endocrinol Metab* **99**:E1–E8.
24. Ghassabian A, Bongers-Schokking JJ, Henrichs J, Jaddoe VWV, Visser TJ, Visser W, de Muinck Keizer-Schrama SMPF, Hooijkaas H, Steegers EAP, Hofman A, Verhulst FC, van der Ende J, de Rijke YB, Tiemeier H 2011 Maternal thyroid function during pregnancy and behavioral problems in the offspring: the generation R study. *Pediatr Res* **69**:454–459.
25. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O’Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, others 1999 Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *New England Journal of Medicine* **341**:549–555.
26. Andersen SL, Laurberg P, Wu CS, Olsen J 2014 Attention deficit hyperactivity disorder and autism spectrum disorder in children born to mothers with thyroid dysfunction: a Danish nationwide cohort study. *BJOG* **121**:1365–1374.
27. Modesto T, Tiemeier H, Peeters RP, Jaddoe VWV, Hofman A, Verhulst FC, Ghassabian A 2015 Maternal Mild Thyroid Hormone Insufficiency in Early Pregnancy and Attention-Deficit/Hyperactivity Disorder Symptoms in Children. *JAMA Pediatr* **169**:838–845.
28. Fetene DM, Betts KS, Alati R 2018 Maternal Prenatal Thyroid Function and Offspring ADHD: Findings From the ALSPAC Cohort. *J Nerv Ment Dis* **206**:859–864.

29. Oostenbroek MHW, Kersten RHJ, Tros B, Kunst AE, Vrijkotte TGM, Finken MJJ 2017 Maternal hypothyroxinaemia in early pregnancy and problem behavior in 5-year-old offspring. *Psychoneuroendocrinology* **81**:29–35.
30. Chevrier J, Harley KG, Kogut K, Holland N, Johnson C, Eskenazi B 2011 Maternal Thyroid Function during the Second Half of Pregnancy and Child Neurodevelopment at 6, 12, 24, and 60 Months of Age. *Journal of Thyroid Research* **2011**:1–13.
31. Andersen SL, Andersen S, Vestergaard P, Olsen J 2018 Maternal Thyroid Function in Early Pregnancy and Child Neurodevelopmental Disorders: A Danish Nationwide Case-Cohort Study. *Thyroid* **28**:537–546.
32. Lazarus JH, Bestwick JP, Channon S, Paradise R, Maina A, Rees R, Chiusano E, John R, Guaraldo V, George LM, Perona M, Dall’Amico D, Parkes AB, Joomun M, Wald NJ 2012 Antenatal thyroid screening and childhood cognitive function. *N Engl J Med* **366**:493–501.
33. Casey BM, Thom EA, Peaceman AM, Varner MW, Sorokin Y, Hirtz DG, Reddy UM, Wapner RJ, Thorp JM, Saade G, Tita ATN, Rouse DJ, Sibai B, Iams JD, Mercer BM, Tolosa J, Caritis SN, VanDorsten JP 2017 Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. *New England Journal of Medicine* **376**:815–825.
34. Guxens M, Ballester F, Espada M, Fernández MF, Grimalt JO, Ibarluzea J, Olea N, Rebagliato M, Tardón A, Torrent M, Vioque J, Vrijheid M, Sunyer J, INMA Project 2012 Cohort Profile: the INMA--INfancia y Medio Ambiente--(Environment and Childhood) Project. *Int J Epidemiol* **41**:930–940.
35. Kooijman MN, Kruithof CJ, van Duijn CM, Duijts L, Franco OH, van IJzendoorn MH, de Jongste JC, Klaver CCW, van der Lugt A, Mackenbach JP, Moll HA, Peeters RP, Raat H, Rings EHHM,

- Rivadeneira F, van der Schroeff MP, Steegers EAP, Tiemeier H, Uitterlinden AG, Verhulst FC, Wolvius E, Felix JF, Jaddoe VWV 2016 The Generation R Study: design and cohort update 2017. *Eur J Epidemiol* **31**:1243–1264.
36. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G 2013 Cohort Profile: The ‘Children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* **42**:111–127.
 37. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A, Ring S, Nelson SM, Lawlor DA 2013 Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. *Int J Epidemiol* **42**:97–110.
 38. ALSPAC Executive Access data and samples. Available at <http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/>. Accessed March 12, 2018.
 39. ALSPAC Executive Research Ethics. Available at <http://www.bristol.ac.uk/alspac/researchers/research-ethics/>. Accessed April 23, 2019.
 40. Lahey BB, Pelham WE, Stein MA, Loney J, Trapani C, Nugent K, Kipp H, Schmidt E, Lee S, Cale M, Gold E, Hartung CM, Willcutt E, Baumann B 1998 Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. *J Am Acad Child Adolesc Psychiatry* **37**:695–702.
 41. Achenbach TM, Rescorla LA 2000 ASEBA preschool forms & profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth and Families.

42. Fisher P, Lucas C 2006 Diagnostic interview schedule for children (DISC-IV) - young child. Columbia University, New York.
43. Rijlaarsdam J, Stevens GWJM, Ende J van der, Hofman A, Jaddoe VWV, Verhulst FC, Tiemeier H 2015 Prevalence of DSM-IV disorders in a population-based sample of 5- to 8-year-old children: the impact of impairment criteria. *Eur Child Adolesc Psychiatry* **24**:1339–1348.
44. Goodman R, Ford T, Richards H, Gatward R, Meltzer H 2000 The Development and Well-Being Assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. *J Child Psychol Psychiatry* **41**:645–655.
45. Wolke D, Waylen A, Samara M, Steer C, Goodman R, Ford T, Lamberts K 2009 Selective drop-out in longitudinal studies and non-biased prediction of behaviour disorders. *The British Journal of Psychiatry* **195**:249–256.
46. Forns J, Sunyer J, Garcia-Esteban R, Porta D, Ghassabian A, Giorgis-Allemand L, Gong T, Gehring U, Sørensen M, Standl M, Sugiri D, Almqvist C, Andiaarena A, Badaloní C, Beelen R, Berdel D, Cesaroni G, Charles M-A, Eriksen KT, Estarlich M, Fernandez MF, Forhan A, Jaddoe VWV, Korek M, Lichtenstein P, Lertxundi A, Lopez-Espinosa M-J, Markevych I, de Nazelle A, Raaschou-Nielsen O, Nieuwenhuijsen M, Pérez-Lobato R, Philippat C, Slama R, Tiesler CMT, Verhulst FC, von Berg A, Vrijkotte T, Nybo Andersen A-M, Heude B, Krämer U, Heinrich J, Tiemeier H, Forastiere F, Pershagen G, Brunekreef B, Guxens M 2018 Air Pollution Exposure During Pregnancy and Symptoms of Attention Deficit and Hyperactivity Disorder in Children in Europe. *Epidemiology* **29**:618–626.
47. Lempinen L, Luntamo T, Sourander A 2019 Changes in mental health service use among 8-year-old children: a 24-year time-trend study. *Eur Child Adolesc Psychiatry* **28**:521–530.

48. La'ulu SL, Roberts WL 2007 Second-trimester reference intervals for thyroid tests: the role of ethnicity. *Clin Chem* **53**:1658–1664.
49. La'ulu SL, Roberts WL 2011 Ethnic differences in first-trimester thyroid reference intervals. *Clin Chem* **57**:913–915.
50. Korevaar TIM, Medici M, de Rijke YB, Visser W, de Muinck Keizer-Schrama SMPF, Jaddoe VWV, Hofman A, Ross HA, Visser WE, Hooijkaas H, Steegers EAP, Tiemeier H, Bongers-Schokking JJ, Visser TJ, Peeters RP 2013 Ethnic differences in maternal thyroid parameters during pregnancy: the Generation R study. *J Clin Endocrinol Metab* **98**:3678–3686.
51. Bøe T, Øverland S, Lundervold AJ, Hysing M 2012 Socioeconomic status and children's mental health: results from the Bergen Child Study. *Soc Psychiatry Psychiatr Epidemiol* **47**:1557–1566.
52. Russell AE, Ford T, Russell G 2015 Socioeconomic Associations with ADHD: Findings from a Mediation Analysis. *PLoS One* **10**:e0128248.
53. Higgins, JP, Thompson, SG 2002 Quantifying heterogeneity in a meta-analysis. *Stat Med* **21**:1539–1558.
54. Ghassabian A, Bongers-Schokking JJ, de Rijke YB, van Mil N, Jaddoe VWV, de Muinck Keizer-Schrama SMPF, Hooijkaas H, Hofman A, Visser W, Roman GC, Visser TJ, Verhulst FC, Tiemeier H 2012 Maternal Thyroid Autoimmunity During Pregnancy and the Risk of Attention Deficit/Hyperactivity Problems in Children: The Generation R Study. *Thyroid* **22**:178–186.
55. Weisskopf MG, Sparrow D, Hu H, Power MC 2015 Biased Exposure-Health Effect Estimates from Selection in Cohort Studies: Are Environmental Studies at Particular Risk? *Environ Health Perspect* **123**:1113–1122.

56. Srichomkwun P, Anselmo J, Liao X-H, Hönes GS, Moeller LC, Alonso-Sampedro M, Weiss RE, Dumitrescu AM, Refetoff S 2017 Fetal Exposure to High Maternal Thyroid Hormone Levels Causes Central Resistance to Thyroid Hormone in Adult Humans and Mice. *The Journal of Clinical Endocrinology & Metabolism* **102**:3234–3240.
57. Kempers MJE, van Tijn DA, van Trotsenburg ASP, de Vijlder JJM, Wiedijk BM, Vulsma T 2003 Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed. *J Clin Endocrinol Metab* **88**:5851–5857.
58. Kempers MJE, van Trotsenburg ASP, van Rijn RR, Smets AMJB, Smit BJ, de Vijlder JJM, Vulsma T 2007 Loss of integrity of thyroid morphology and function in children born to mothers with inadequately treated Graves' disease. *J Clin Endocrinol Metab* **92**:2984–2991.
59. Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff S 2004 Fetal Loss Associated With Excess Thyroid Hormone Exposure. *JAMA* **292**:691–695.
60. Medici M, Timmermans S, Visser W, de Muinck Keizer-Schrama SMPF, Jaddoe VWW, Hofman A, Hooijkaas H, de Rijke YB, Tiemeier H, Bongers-Schokking JJ, Visser TJ, Peeters RP, Steegers EAP 2013 Maternal thyroid hormone parameters during early pregnancy and birth weight: the Generation R Study. *J Clin Endocrinol Metab* **98**:59–66.
61. León G, Murcia M, Rebagliato M, Álvarez-Pedrerol M, Castilla AM, Basterrechea M, Iñiguez C, Fernández-Somoano A, Blarduni E, Foradada CM, Tardón A, Vioque J 2015 Maternal Thyroid Dysfunction during Gestation, Preterm Delivery, and Birthweight. *The Infancia y Medio Ambiente Cohort, Spain. Paediatr Perinat Epidemiol* **29**:113–122.

62. Pettersson E, Sjölander A, Almqvist C, Anckarsäter H, D’Onofrio BM, Lichtenstein P, Larsson H
2015 Birth weight as an independent predictor of ADHD symptoms: A within-twin pair analysis. *J Child Psychol Psychiatry* **56**:453–459.
63. Levie D, Korevaar TIM, Bath SC, Murcia M, Dineva M, Llop S, Espada M, van Herwaarden AE, de
Rijke YB, Ibarluzea JM, Sunyer J, Tiemeier H, Rayman MP, Guxens M, Peeters RP 2019 Association
of maternal iodine status with child IQ: a meta-analysis of individual-participant data. *J Clin
Endocrinol Metab*.
64. Vermiglio F, Presti L, P V, Moleti M, Sidoti M, Tortorella G, Scaffidi G, Castagna MG, Mattina F,
Violi MA, Crisà A, Artemisia A, Trimarchi F 2004 Attention Deficit and Hyperactivity Disorders in
the Offspring of Mothers Exposed to Mild-Moderate Iodine Deficiency: A Possible Novel Iodine
Deficiency Disorder in Developed Countries. *J Clin Endocrinol Metab* **89**:6054–6060.
65. Korevaar TIM, de Rijke YB, Chaker L, Medici M, Jaddoe VWV, Steegers EAP, Visser TJ, Peeters RP
2017 Stimulation of Thyroid Function by Human Chorionic Gonadotropin During Pregnancy: A
Risk Factor for Thyroid Disease and a Mechanism for Known Risk Factors. *Thyroid* **27**:440–450.
66. Korevaar TIM, Tiemeier H, Peeters RP 2018 Clinical associations of maternal thyroid function with
foetal brain development: Epidemiological interpretation and overview of available evidence.
Clinical Endocrinology **89**:129–138.
67. Murray DW, Kollins SH, Hardy KK, Abikoff HB, Swanson JM, Cunningham C, Vitiello B, Riddle MA,
Davies M, Greenhill LL, McCracken JT, McGough JJ, Posner K, Skrobala AM, Wigal T, Wigal SB,
Ghuman JK, Chuang SZ 2007 Parent versus Teacher Ratings of Attention-Deficit/Hyperactivity
Disorder Symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment
Study (PATs). *Journal of Child and Adolescent Psychopharmacology* **17**:605–619.

68. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management 2011 ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics* **128**:1007–1022.

Table 1 Distribution of maternal and child characteristics

	INMA (N=1073)	Generation R (N=3812)	ALSPAC (N=2784)	<i>P</i> -value
ADHD, %	5.3	3.2	2.0	<0.001
ADHD symptoms > P90, %	10.4	10.3	10.3	0.990
Maternal TSH, median (IQR), mIU/L	1.25 (0.82-1.82)	1.38 (0.87-2.07)	1.02 (0.64-1.49)	<0.001
Maternal FT4, median (IQR), pmol/L	10.6 (9.7-11.5)	14.8 (13.2-16.7)	16.1 (14.8-17.6)	<0.001
TPOAb positivity, %	NA	5.8	12.8	<0.001
Gestational age at blood sampling, mean (SD), weeks ^a	13.1 (1.3)	13.4 (1.9)	11.0 (3.2)	<0.001
Maternal educational level, % ^a				<0.001
Low	20.8	6.2	24.0	
Medium	42.5	40.8	61.6	
High	36.6	53.0	14.4	
Maternal ethnicity/country of birth, % ^a				<0.001
Spanish	93.8	NA	NA	
Other, non-Spanish	6.2	NA	NA	
Dutch	NA	60.6	NA	
Indonesian	NA	3.3	NA	
Cape verdian	NA	3.0	NA	
Turkish	NA	6.9	NA	
Other, non-western	NA	17.0	NA	
Other, western	NA	9.2	NA	
White	NA	NA	98.6	
Non-white	NA	NA	1.4	
Maternal age, mean (SD), years	31.6 (3.9)	30.7 (4.6)	28.1 (4.6)	<0.001
Parity, % ^a				<0.001
0	57.0	59.6	47.9	
1	36.7	29.9	34.7	
≥2	6.3	10.5	17.4	
Smoking during pregnancy, % ^a				<0.001
Never	70.2	74.9	79.6	
At the beginning of pregnancy	12.9	9.6	4.5	
Continued smoking	16.9	15.5	15.9	
Pre-pregnancy BMI, median (IQR), kg/m ² ^a	22.5 (20.8-25.0)	22.5 (20.8-25.1)	22.1 (20.5-24.2)	<0.001
Child female sex, % ^a	48.9	50.1	48.5	0.410

P-value for differences was calculated using the Chi-square test for categorical variables, one-way analysis of variance (ANOVA) for continuous normal-distributed variables, and Kruskal-Wallis test for continuous non-normal distributed variables. NA, not available. BMI, body mass index.

^a values do not take into account missing data (0%, 0.2%, 0% for gestational age; 0.3%, 3.2%, 2.5% for maternal education; 0.1%, 0%, 2.9% for maternal ethnicity/country of birth; 0.2%, 0%, 2.9% for parity; 1.4%, 9.0%, 1.7% for smoking; 0%, 15.6%, 8.8% for pre-pregnancy BMI, 0.1%, 0%, 0% for child sex in INMA, Generation R, and ALSPAC respectively).

Table 2 Association of maternal FT4 and TSH concentrations during pregnancy with child ADHD and with an ADHD symptom score $\geq 90^{\text{th}}$ percentile

	ADHD			ADHD symptoms score $\geq 90^{\text{th}}$ percentile		
	n/N ^a	OR (95% CI)	P-value	n/N ^b	OR (95% CI)	P-value
<i>Free thyroxine</i>						
Pooled	232/7355	1.1 (1.0-1.3)	0.060	779/6768	1.0 (0.9-1.1)	0.554
INMA	57/1016	1.3 (0.9-1.7)	0.126	111/952	1.3 (1.0-1.6)	0.040
Generation R	121/3658	1.0 (0.8-1.3)	0.747	390/3384	1.0 (0.8-1.1)	0.420
ALSPAC	54/2681	1.2 (0.9-1.7)	0.225	278/2432	1.1 (0.9-1.3)	0.294
<i>Thyrotropin</i>						
Pooled	230/7299	0.9 (0.8-1.1)	0.385	777/6712	0.9 (0.9-1.0)	0.073
INMA	56/1009	0.9 (0.7-1.3)	0.562	110/945	0.8 (0.7-1.0)	0.114
Generation R	119/3633	0.9 (0.8-1.1)	0.323	388/3359	1.0 (0.9-1.1)	0.943
ALSPAC	55/2657	0.9 (0.7-1.2)	0.641	279/2408	0.9 (0.8-1.0)	0.046
		1.2 (1.0-1.4) ^c	0.027			

Reported odds ratio's and 95% confidence intervals are increase in odds per SD of logtransformed FT4 or TSH. Analyses were performed using logistic regression and adjusted for gestational age at blood sampling, maternal education, maternal ethnicity/country of birth, age, parity, smoking during pregnancy, pre-pregnancy body mass index, and child sex. Cohort specific estimates were also adjusted for child age at ADHD ascertainment and sub-cohort in INMA.

^a n=children with ADHD, N=children without ADHD

^b n=children with a symptom score $\geq 90^{\text{th}}$ percentile, N=children with a symptom score $< 90^{\text{th}}$ percentile.

^c A quadratic term (TSH SD score $\wedge 2$) was added to the model, indicating a non-linear association.

Table 3 Pooled association of maternal FT4 and TSH concentrations during pregnancy with child ADHD and with an ADHD symptom score above the 90th percentile, stratified by tertile of gestational age

ADHD							ADHD symptoms above the 90 th percentile		
	gestational age median (range)	N	% with ADHD	OR (95% CI)	P-value	N	% score >P90	OR (95% CI)	P-value
Free thyroxine									
Tertile 1	10.0 (4.0-11.8)	2523	2.4	1.1 (0.9-1.5)	0.356	2503	9.8	1.2 (1.0-1.4)	0.027
Tertile 2	12.6 (11.8-13.5)	2580	3.5	1.2 (1.0 -1.6)	0.064	2580	11.1	1.0 (0.9-1.2)	0.884
								1.1 (1.0-1.2) ^a	0.027
Tertile 3	15.1 (13.5-18.0)	2480	3.2	1.0 (0.8-1.3)	0.799	2470	10.1	0.9 (0.7-1.0)	0.045
Thyrotropin									
Tertile 1	10.0 (4.0-11.8)	2500	2.4	0.9 (0.7-1.2)	0.510	2480	9.9	0.8 (0.7-0.9)	0.006
Tertile 2	12.6 (11.8-13.5)	2562	3.5	1.0 (0.8-1.2)	0.836	2562	11.1	0.9 (0.8-1.1)	0.284
Tertile 3	15.1 (13.5-18.0)	2461	3.2	0.9 (0.7-1.2)	0.436	2451	10.1	1.0 (0.9-1.2)	0.595

Reported odds ratio's and 95% confidence intervals are increase in odds per SD of logtransformed FT4 or TSH. Analyses were performed using logistic regression and adjusted for gestational age at blood sampling, maternal education, maternal ethnicity/country of birth, age, parity, smoking during pregnancy, pre-pregnancy body mass index, and child sex.

^a A quadratic term (FT4 SD score ^2) was added to the model, indicating a non-linear association. NA, not applicable.

Figure 1 Flowchart of the selection of the study population

TSH: thyrotropin; FT4: free thyroxine; SD: standard deviation; ADHD: Attention Deficit Hyperactivity Disorder; INMA: INfancia y Medio Ambiente; ALSPAC: Avon Longitudinal Study of Parents and Children

Supplementary material

Supplement to: Deborah Levie, Tim IM Korevaar, Tessa A Mulder, Sarah C Bath, Mariana Dineva, Maria-Jose Lopez-Espinosa, Mikel Basterrechea, Loreto Santa Marina, Marisa Rebagliato, Jordi Sunyer, Margaret P Rayman, Henning Tiemeier, Robin P Peeters, Mònica Guxens. Thyroid Function in Early Pregnancy and Child Attention Deficit Hyperactivity Disorder: An Individual-Participant Meta-Analysis

Serum measurements

In INMA, the between-assay coefficients of variation for low, medium, and high hormone concentrations were 6.1%, 4.1%, and 4.0% for FT4 respectively, and 3.0%, 3.1%, and 2.6% for TSH. The intra-assay coefficients of variation were 3.7%, 3.0%, and 3.3% for FT4 respectively, and 7.7%, 2.1%, and 1.7% for TSH (for AutoDEL-FIA, PerkinElmer Life and Analytical Sciences, Wallac Oy, Turku, Finland). In Generation R, the intra- and interassay coefficients of variation were < 5.4% for FT4 with a range of 14.3-25.0 pmol/L and < 4.1% for TSH with a range of 3.97-22.7 mIU/L (for Vitros ECI immunodiagnostic; Ortho Clinical Diagnostics, Rochester, NY). In ALSPAC, FT4, TSH, and TPOAb measurements were performed using Abbott Architect i2000 with functional sensitivity of 0.05 mIU/L or less. Inter- and intra-assay coefficients of variation were less than 5% for all analytes

Supplementary Table 1 Distribution and comparison of maternal and child characteristics in the included and excluded population

	INMA			Generation R			ALSPAC		
	Included (n=1073)	Excluded (n=913)	<i>P</i> -value	Included (n=3812)	Excluded (n=3206)	<i>P</i> -value	Included (n=2784)	Excluded (n=2093)	<i>P</i> -value
Maternal TSH, median (IQR), mIU/L	1.25 (0.82-1.82)	1.23 (0.79-1.87)	0.886	1.38 (0.87-2.07)	1.27 (0.78-1.97)	<0.001	1.02 (0.64-1.49)	0.97 (0.62-1.43)	0.013
Maternal FT4, median (IQR), pmol/L	10.6 (9.7-11.5)	10.5 (9.5-11.6)	0.170	14.8 (13.2-16.7)	14.6 (12.9-16.7)	0.072	16.1 (14.8-17.6)	16.4 (14.9-17.9)	0.003
TPOAb positivity, %	NA	NA		5.8	6.4	0.360	12.8	12.1	0.415
Gestational age at blood sampling, mean (SD), weeks	13.1 (1.3)	13.2 (1.3)	0.165	13.4 (1.9)	13.7 (2.1)	<0.001	11.0 (3.2)	11.0 (3.2)	0.997
Maternal educational level, %									
Low	20.8	30.1	<0.001	6.2	15.3	<0.001	24.0	38.5	<0.001
Medium	42.5	39.6		40.8	51.8		61.6	53.1	
High	36.6	30.3		53.0	32.9		14.4	8.4	
Maternal ethnicity, %									
Spanish	93.8	86.7	<0.001	NA	NA	<0.001	NA	NA	<0.001
Other, non-Spanish	6.2	13.3		NA	NA		NA	NA	
Dutch	NA	NA		60.6	40.1		NA	NA	
Indonesian	NA	NA		3.3	2.6		NA	NA	
Cape verdian	NA	NA		3.0	5.8		NA	NA	
Turkish	NA	NA		6.9	10.5		NA	NA	
Other, non-western	NA	NA		17.0	32.3		NA	NA	
Other, western	NA	NA		9.2	8.7		NA	NA	
White	NA	NA		NA	NA		98.6	96.9	
Non-white	NA	NA		NA	NA		1.4	3.1	
Maternal age, mean(SD), years	31.6 (3.9)	30.9 (4.6)	<0.001	30.7 (4.6)	28.6 (5.4)	<0.001	28.1 (4.6)	26.4 (5.0)	<0.001

Supplementary Table 1 Distribution and comparison of maternal and child characteristics in the included and excluded population (continued)

	INMA			Generation R			ALSPAC		
	Included (n=1073)	Excluded (n=913)	<i>P</i> -value	Included (n=3812)	Excluded (n=3206)	<i>P</i> -value	Included (n=2784)	Excluded (n=2093)	<i>P</i> -value
Parity, %									
0	57.0	52.9	0.106	59.6	52.8	<0.001	47.9	43.5	<0.001
1	36.7	38.9		29.9	29.5		34.7	33.6	
≥2	6.3	8.2		10.5	17.7		17.4	22.9	
Maternal smoking, %									
Never smoked	70.2	66.1	0.144	74.9	68.0	<0.001	79.6	68.3	<0.001
Smoked at the beginning of pregnancy	12.9	15.1		9.6	9.0		4.5	6.6	
Continued smoking	16.9	18.8		15.5	23.0		15.9	25.1	
Pre-pregnancy BMI, median (IQR), kg/m ²	22.5 (20.8-25.0)	22.5 (20.7-25.2)	0.738	22.5 (20.8-25.1)	22.7 (20.7-25.7)	0.119	22.1 (20.5-24.2)	22.2 (20.5-24.6)	0.145
Child female sex, %	48.9	48.6	0.898	50.1	48.6	0.226	48.5	47.6	0.520

P-value for differences calculated using Chi-square test for categorical variables, Student’s t-test for continuous normal-distributed variables, and Wilcoxon rank-sum test for continuous non-normal distributed variables. NA: not available. Numbers are based on unimputed data; percentages add up to 100% without taking into account missing values.

Supplementary Table 2 Distribution and comparison of maternal and child characteristics among the mother-child pairs with available data on thyroid function during pregnancy and child ADHD symptoms and those mothers whose children did not underwent an ADHD assessment

	INMA			Generation R			ALSPAC		
	ADHD data (n=1130)	no ADHD data (n=817)	<i>P</i> -value	ADHD data (n=3935)	no ADHD data (n=1954)	<i>P</i> -value	ADHD data (n=2960)	no ADHD data (n=1898)	<i>P</i> -value
Maternal TSH median (IQR), mIU/L	1.26 (0.83-1.87)	1.21 (0.79-1.83)	0.354	1.38 (0.86-2.08)	1.27 (0.80-1.95)	<0.001	1.01 (0.63-1.49)	0.97 (0.63-1.42)	0.054
Maternal FT4, median (IQR), pmol/L	10.6 (9.7-11.6)	10.5 (9.5-11.5)	0.025	14.9 (13.2-16.7)	14.6 (12.9-16.6)	0.007	16.2 (14.8-17.7)	16.3 (14.9-17.9)	0.053
TPOAb positivity, %	NA	NA	NA	6.3	5.7	0.401	13.1	11.6	0.115
Gestational age at blood sampling, mean (SD), weeks	13.1 (1.3)	13.2 (1.3)	0.202	13.7 (2.1)	13.4 (1.9)	<0.001	11.0 (3.2)	10.9 (3.2)	0.502
Maternal educational level, %									
Low	20.9	31.3	<0.001	6.3	18.0	<0.001	23.8	40.6	<0.001
Medium	42.2	39.4		40.7	55.3		61.6	52.1	
High	36.9	29.3		53.0	26.7		14.7	7.2	
Maternal ethnicity, %									
Spanish	94.1	85.8	<0.001	NA	NA	<0.001	NA	NA	<0.001
Other, non-Spanish	5.9	14.3		NA	NA		NA	NA	
Dutch	NA	NA		61.0	33.3		NA	NA	
Indonesian	NA	NA		3.3	2.4		NA	NA	
Cape verdian	NA	NA		3.0	6.5		NA	NA	
Turkish	NA	NA		6.9	11.2		NA	NA	
Other, non-western	NA	NA		16.9	37.8		NA	NA	
Other, western	NA	NA		9.1	8.8		NA	NA	
White	NA	NA		NA	NA		98.5	96.7	
Non-white	NA	NA		NA	NA		1.5	3.3	
Maternal age, mean(SD), years	31.6 (4.0)	30.8 (4.6)	<0.001	30.7 (4.6)	27.8 (5.3)	<0.001	28.2 (4.5)	26.0 (4.9)	<0.001

Supplementary Table 2 Distribution and comparison of maternal and child characteristics among the mother-child pairs with available data on thyroid function during pregnancy and child ADHD symptoms and those mothers whose children did not underwent an ADHD assessment (continued)

	INMA			Generation R			ALSPAC		
	ADHD data (n=1130)	no ADHD data (n=817)	<i>P</i> -value	ADHD data (n=3935)	no ADHD data (n=1954)	<i>P</i> -value	ADHD data (n=2960)	no ADHD data (n=1898)	<i>P</i> -value
Parity, %									
0	56.7	52.8	0.090	59.4	51.2	<0.001	48.4	42.2	<0.001
1	37.0	38.7		30.1	29.0		34.5	33.8	
≥2	6.4	8.6		10.5	19.5		17.1	24.0	
Maternal smoking, %									
Never smoked	70.6	64.9	0.029	74.9	65.6	<0.001	79.7	66.8	<0.001
Smoked at the beginning of pregnancy	12.6	15.8		9.6	8.9		4.5	6.8	
Continued smoking	16.9	19.3		15.5	25.5		15.8	26.4	
Pre-pregnancy BMI, median (IQR), kg/m ²	22.6 (20.8-25.1)	22.4 (20.7-25.2)	0.401	22.5 (20.8-25.1)	22.7 (20.6-25.9)	0.195	22.1 (20.5-24.2)	22.2 (20.5-24.6)	0.155
Child female sex, %	48.7	48.4	0.895	50.0	47.9	0.136	48.2	47.9	0.797

The distribution of characteristics is compared between the group “enrolled ≤18 week and data on maternal thyroid function N=12694” and the group “maternal thyroid function and child ADHD data collected N=8025”, as shown in Figure 1. *P*-value for differences calculated using Chi-square test for categorical variables, Student’s *t*-test for continuous normal-distributed variables, and Wilcoxon rank-sum test for continuous non-normal distributed variables. NA: not available. Numbers are based on unimputed data; percentages add up to 100% without taking into account missing values.

(a) FT4 and ADHD

(c) FT4 and symptom score ≥ 90 th percentile

(b) TSH and ADHD

(d) TSH and symptom score ≥ 90 th percentile

Supplementary Figure 1 Association of maternal FT4 and TSH concentrations during pregnancy with child ADHD and with an ADHD symptom score ≥ 90 th percentile. Associations shown as effect estimate (dot) with the 95% CI per cohort and overall as estimated by a random-effects meta-analysis (diamond). Statistical heterogeneity was explored and quantified using the Cochran Q test and the I^2 statistic, which is the proportion of total variation in the estimates that is due to heterogeneity between studies. The models were adjusted for maternal age, parity, pre-pregnancy BMI, smoking during pregnancy, ethnicity/country of birth, maternal educational level, gestational age at blood sampling, child sex, and sub-cohort in INMA.

Supplementary Table 3 Association of maternal FT4 during early pregnancy with child ADHD symptom scores on a continuous scale.

	n	IRR (95% CI)	<i>P</i> -value
INMA	1063	1.05 (0.98 to 1.14)	0.187
Generation R	3657	0.98 (0.95 to 1.01)	0.204
ALSPAC	2710	0.99 (0.92 to 1.06)	0.692

Reported incidence rate ratio (IRR) and 95% confidence intervals represent the change in ADHD symptoms per SD of logtransformed FT4 in terms of a percentage increase or decrease, with the precise percentage determined by the amount the IRR is either above or below 1. Analyses were performed using negative binomial regression models and adjusted for gestational age at blood sampling, maternal education, maternal ethnicity/country of birth, age, parity, smoking during pregnancy, pre-pregnancy body mass index, child sex, child age, and sub-cohort in INMA.

Supplementary Table 4 Continuous association of maternal TSH during early pregnancy with child ADHD symptom scores on a continuous scale.

	n	IRR (95% CI)	<i>P</i> -value
INMA	1055	0.94 (0.87 to 1.02)	0.144
Generation R	3630	1.00 (0.97 to 1.03)	0.928
ALSPAC	2687	0.97 (0.91 to 1.03)	0.282

Reported incidence rate ratio (IRR) and 95% confidence intervals represent the change in ADHD symptoms per SD of logtransformed TSH in terms of a percentage increase or decrease, with the precise percentage determined by the amount the IRR is either above or below 1. Analyses were performed using negative binomial regression models and adjusted for gestational age at blood sampling, maternal education, maternal ethnicity/country of birth, age, parity, smoking during pregnancy, pre-pregnancy body mass index, child sex, child age, and sub-cohort in INMA.